Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939606 | 1.00 | MMP13 (0.30) | MMP13 | |
| SCHEMBL9904821 | 1.00 | MMP13 (0.30) | MMP13 | |
| SCHEMBL19846867 | 0.90 | — | — | |
| SCHEMBL30939535 | 0.90 | — | — | |
| SCHEMBL30939534 | 0.90 | — | — | |
| SCHEMBL9904667 | 0.90 | — | — | |
| SCHEMBL17280423 | 0.89 | — | — | |
| SCHEMBL15011856 | 0.89 | — | — | |
| SCHEMBL30939643 | 0.89 | — | — | |
| SCHEMBL21857962 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10555945-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-02-11 | — | — | US | disclosed |
| US-20190000849-A1 | NOVEL COMPOUNDS | AUTIFONY THERAPEUTICS LIMITED | 2019-01-03 | — | — | US | disclosed |
| US-20180036308-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2018-02-08 | — | — | US | disclosed |
| US-20180036308-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2018-02-08 | — | — | US | disclosed |
| US-20160317537-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2016-11-03 | — | — | US | disclosed |
| US-20160317537-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2016-11-03 | — | — | US | disclosed |
| US-9422272-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-9422272-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20150336936-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2015-11-26 | — | — | US | disclosed |
| US-20150336936-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336936-A1 | NOVEL COMPOUNDS | KCNN3, KCNN2, KCNN1 | MMP13 4640/4885 |
| US-20190000849-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | MMP13 4544/4885 |
| US-20160317537-A1 | NOVEL COMPOUNDS | KCNN3, KCNN2, KCNN1 | MMP13 4640/4885 |
| US-10555945-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | MMP13 4302/4885 |
| US-20180036308-A1 | NOVEL COMPOUNDS | CYFIP1, CYFIP2, ZFX | MMP13 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.